Support of renal blood flow after ischaemic-reperfusion injury by endogenous formation of nitric oxide and of cyclo-oxygenase vasodilator metabolites - PubMed (original) (raw)
Support of renal blood flow after ischaemic-reperfusion injury by endogenous formation of nitric oxide and of cyclo-oxygenase vasodilator metabolites
J P Cristol et al. Br J Pharmacol. 1993 May.
Abstract
1. Ischaemia-reperfusion injury in the kidney is associated with a loss of autoregulation, an increase in renal vascular resistance (RVR), a decrease of renal blood flow (RBF) and ultimately acute renal failure. The aim of this study was to investigate the role of the release of endogenous nitric oxide (NO) in the recovery of RBF after ischaemic injury of the renal vascular bed. 2. Anaesthetized rats (thiopentone sodium; 120 mg kg-1, i.p.) were submitted to acute renal ischaemia followed by 2 or 6 h of reperfusion (I/R). Reperfusion was associated with a significant reduction in RBF, an increase in RVR, and an impairment of the vasodilator effect of acetylcholine (ACh). 3. NG-nitro-L-arginine methyl ester (L-NAME, 30 micrograms kg-1 min-1, i.v., n = 5) significantly prevented the recovery of RBF after I/R injury. Similarly, inhibition of prostanoid formation with indomethacin (5 mg kg-1, i.v., n = 4) significantly enhanced the rise in RVR associated with I/R injury. 4. Infusion of L-arginine (L-Arg; 1 or 3 mg kg-1 min-1, i.v., n = 5 and 4, respectively) or D-Arg (1 mg kg-1 min-1, i.v., n = 6), starting 30 min after occlusion, did not improve the recovery of RBF. Furthermore, infusion of L-Arg (20 mg kg-1 min-1 for 15 min; n = 4) had no effect on the I/R-induced impairment of the vasodilator responses to ACh. 5. To elucidate the relative importance of the constitutive and inducible NO synthase isoforms for the formation of NO after I/R, calcium-dependent (constitutive) and calcium-independent (inducible) NO synthase activities were measured in kidney homogenates obtained from ischaemic or non-ischaemic kidneys. A calcium-independent NO synthase activity was not detectable in kidney homogenates obtained from either sham-operated control rats or from animals subjected to I/R. Moreover, dexamethasone(3 mg kg-1, i.v., 60 min prior to I/R, n = 6), an inhibitor of the induction of NO synthase,had no effect on either RBF or RVR in rats subjected to I/R. In contrast to I/R, lipopolysaccaride(LPS, endotoxin; 5 mg kg-1, i.p., n = 3) caused a significant induction of a calcium-independent NO synthase activity in the kidney.6. These results confirm the importance of the release of vasodilator cyclo-oxygenase metabolites in the compromised renal circulation and indicate that the formation of NO derived from the constitutive, but not the inducible NO synthase, is also important for the maintenance of RBF after I/R injury of the renal vascular bed.
Similar articles
- Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats.
Conger J, Robinette J, Villar A, Raij L, Shultz P. Conger J, et al. J Clin Invest. 1995 Jul;96(1):631-8. doi: 10.1172/JCI118078. J Clin Invest. 1995. PMID: 7542287 Free PMC article. - Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids.
Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Swierkosz TA, et al. Br J Pharmacol. 1995 Apr;114(7):1335-42. doi: 10.1111/j.1476-5381.1995.tb13353.x. Br J Pharmacol. 1995. PMID: 7541688 Free PMC article. - In vivo regulation of endothelium-dependent vasodilation in the rat renal circulation and the effect of streptozotocin-induced diabetes.
Edgley AJ, Tare M, Evans RG, Skordilis C, Parkington HC. Edgley AJ, et al. Am J Physiol Regul Integr Comp Physiol. 2008 Sep;295(3):R829-39. doi: 10.1152/ajpregu.00861.2007. Epub 2008 Jul 16. Am J Physiol Regul Integr Comp Physiol. 2008. PMID: 18635451 - Nitric oxide in essential and renal hypertension.
MacAllister R, Vallance P. MacAllister R, et al. J Am Soc Nephrol. 1994 Oct;5(4):1057-65. doi: 10.1681/ASN.V541057. J Am Soc Nephrol. 1994. PMID: 7531511 Review. - The biological and pharmacological role of nitric oxide in platelet function.
Radomski MW, Moncada S. Radomski MW, et al. Adv Exp Med Biol. 1993;344:251-64. doi: 10.1007/978-1-4615-2994-1_20. Adv Exp Med Biol. 1993. PMID: 7516113 Review. No abstract available.
Cited by
- Genetic Deletion of Vasohibin-2 Exacerbates Ischemia-Reperfusion-Induced Acute Kidney Injury.
Miyake H, Tanabe K, Tanimura S, Nakashima Y, Morioka T, Masuda K, Sugiyama H, Sato Y, Wada J. Miyake H, et al. Int J Mol Sci. 2020 Jun 26;21(12):4545. doi: 10.3390/ijms21124545. Int J Mol Sci. 2020. PMID: 32604722 Free PMC article. - Low-dose testosterone protects against renal ischemia-reperfusion injury by increasing renal IL-10-to-TNF-α ratio and attenuating T-cell infiltration.
Patil CN, Wallace K, LaMarca BD, Moulana M, Lopez-Ruiz A, Soljancic A, Juncos LA, Grande JP, Reckelhoff JF. Patil CN, et al. Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F395-403. doi: 10.1152/ajprenal.00454.2015. Epub 2016 Jun 1. Am J Physiol Renal Physiol. 2016. PMID: 27252490 Free PMC article. - Preventive Role of Endothelin Antagonist on Kidney Ischemia: Reperfusion Injury in Male and Female Rats.
Afyouni NE, Halili H, Moslemi F, Nematbakhsh M, Talebi A, Shirdavani S, Maleki M. Afyouni NE, et al. Int J Prev Med. 2015 Dec 23;6:128. doi: 10.4103/2008-7802.172549. eCollection 2015. Int J Prev Med. 2015. PMID: 26900442 Free PMC article. - Renal endothelial dysfunction in acute kidney ischemia reperfusion injury.
Basile DP, Yoder MC. Basile DP, et al. Cardiovasc Hematol Disord Drug Targets. 2014;14(1):3-14. doi: 10.2174/1871529x1401140724093505. Cardiovasc Hematol Disord Drug Targets. 2014. PMID: 25088124 Free PMC article. Review. - Role of medullary blood flow in the pathogenesis of renal ischemia-reperfusion injury.
Regner KR, Roman RJ. Regner KR, et al. Curr Opin Nephrol Hypertens. 2012 Jan;21(1):33-8. doi: 10.1097/MNH.0b013e32834d085a. Curr Opin Nephrol Hypertens. 2012. PMID: 22080855 Free PMC article. Review.
References
- J Cardiovasc Pharmacol. 1991;17 Suppl 7:S165-8 - PubMed
- Am J Physiol. 1992 Mar;262(3 Pt 2):H888-96 - PubMed
- Br J Pharmacol. 1992 Mar;105(3):557-62 - PubMed
- Jpn J Pharmacol. 1992 Feb;58(2):147-55 - PubMed
- Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8711-5 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous